



Third international symposium on drug-impaired driving

23 October 2017

The symposium is a collaborative effort between the Canadian Centre on Substance Use and Addiction (CCSA), the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the US National Institute on Drug Abuse International Program (NIDA) and the New Zealand Drug Foundation.

23 October 2017, Lisbon (09.00 – 17.30)

Opening and welcome Alexis Goosdeel, EMCDDA Rita Notarandrea, CCSA Steve Gust, NIDA International Program
Introductory session – Drugs and driving in 2017: issues and developments Doug Beirness, CCSA
Panel session I – Contemporary challenges for regulatory models Which approach to take – a conceptual overview — Brendan Hughes, EMCDDA Where should the limit be? Defining per se laws — Vigdis Vindenes, Norway Assessing impact: update from the UK — Elizabeth Reed, United Kingdom
Panel session II – Advances in drug testing, screening and detection Approaches to Field Impairment Testing — Amy Porath and Doug Beirness, CCSA Drug level and impairment – how do we measure this? — Mario Dias, Portugal Informing an evidence-based cannabis and driving policy: reflections from a UK perspective — Kim Wolff, United Kingdom
Lunch break
Panel session III – Changes in cannabis policy: implications for impaired driving – special session Case examples: Jan Ramaekers, the Netherlands; Darrin Grondel, United States; Glenn Davis, United States; Public Safety Canada
Panel session IV – Future perspectives Interventions from WHO, Global Road Safety Partnership, ICADTS
Closing remarks

Venue:

Lisbon Congress Centre
Praça das Indústrias, nº1
1300-307 Lisbon

More information on the events page:
www.emcdda.europa.eu/meetings/2017/3rd-symposium-drug-impaired-driving